Europe’s medical devices industry saw a rise of 27.9% in overall deal activity during Q2 2019, when compared to the four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 87 deals worth $954.77m were announced for the region during Q2 2019, against the last four-quarter average of 68 deals.

Of all the deal types, venture financing saw most activity in Q2 2019 with 53, representing a 60.9% share for the region.

In second place was M&A with 26 deals, followed by private equity deals with eight transactions, respectively capturing a 29.9% and 9.2% share of the overall deal activity for the quarter.

In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $620.59m, while venture financing and private equity deals totalled $290.82m and $43.36m, respectively.

Europe medical devices industry deals in Q2 2019: Top deals

The top five medical devices deals accounted for 71.5% of the overall value during Q2 2019.

The combined value of the top five medical devices deals stood at $682.99m, against the overall value of $954.77m recorded for the quarter. The top announced medical devices deal tracked by GlobalData in Q2 2019 was Bracco Imaging’s $475m acquisition of Blue Earth Diagnostics.

In second place was the $72.94m venture financing of BioSerenity by BPI France, Dassault Systemes, IDInvest Partners and LBO France and in third place was Revenio Italy’s $66.66m acquisition of CenterVue.

The $38.5m venture financing of DNA Script by BPI France, IDInvest Partners, Illumina Ventures, Kurma Partners, Life Sciences Partners, Merck Ventures and Sofinnova Partners and Tikehau Capital’s private equity deal with Medtrade Products for $29.9m held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.